Invasive Pneumococcal Disease Serotypes Decline
New research shows a drop in specific pneumococcal strains among young children following vaccine adoption.
Updated on Oct. 23, 2026 in Children’s Health
Live Poll
Do you trust that updated vaccines are effectively reducing severe childhood infections in your area?
Recent surveillance data reveals a decline in invasive pneumococcal disease caused by PCV20-added serotypes in children younger than 24 months. The share of cases attributed to these strains fell from 27.8% in 2018-2023 to 17.9% in the 2024-2025 period.
Why it matters
The findings help clinicians and public health officials understand the shifting landscape of pneumococcal infections following the 2023 recommendation for PCV20 use in children. Monitoring these changes is essential for tracking vaccine effectiveness against evolving serotypes.
A study of 968 culture-proven cases across 12 children's hospitals found 9.7% of isolates were nonsusceptible to penicillin and 1.6% were nonsusceptible to ceftriaxone. Researchers used the Fisher exact test to compare 2018-2023 data with 2024-2025 results.
The players
IDWeek
This is an annual scientific meeting where experts share findings on infectious diseases and public health.
Texas Children's Hospital
This institution served as a research laboratory site for the multi-center study on pneumococcal disease.
The details
The proportion of invasive pneumococcal disease cases involving children aged 59 months or younger decreased from 63.4% to 50.8% between the study periods. While bacteremia as a primary diagnosis declined from 36.9% to 27.8%, cases of mastoiditis rose from 11.1% to 17.7%.
Timeline
Surveillance of IPD among children has been conducted since 1993.
The pre-PCV20 study period occurred from 2018 to 2023.
PCV20 was recommended for use in children in June 2023.
The post-PCV20 study period for data collection took place in 2024-2025.
Findings were presented at IDWeek 2026 on October 21-24, 2026.
Health Landscape
This research provides empirical data on how the June 2023 PCV20 recommendation for children is altering the distribution of invasive pneumococcal disease. The study tracks how these vaccine guidelines shift the burden of specific serotypes compared to prior decades of surveillance.
The study suggests that while certain vaccine-targeted strains are decreasing, providers must remain vigilant regarding non-vaccine serotypes like 3 and 19F. Parents and patients should continue to follow pediatric vaccination schedules as recommended by their healthcare providers.
The takeaway
Ongoing monitoring of these infections ensures that medical strategies remain effective against evolving bacterial strains. Clinicians and families can use these insights to stay informed about how vaccination programs protect pediatric health.
What happens next
Ongoing surveillance of invasive pneumococcal disease will continue to monitor the long-term effectiveness of the vaccine.
Further reading
For more information on pediatric immunity and vaccine updates, visit the Children’s Health section.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Do you trust that updated vaccines are effectively reducing severe childhood infections in your area?
